Stock events for Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals' stock price has been impacted by several significant events. The company reported strong financial performance with $521.3 million in net product sales for 2025, a 55% increase from 2024. Mirum reported a Q4 2025 loss of $0.11 per share, missing estimates, but revenues beat estimates. Mirum completed the acquisition of Bluejay Therapeutics in January 2026. Health Canada authorized the LIVMARLI tablet formulation in February 2026. The company provided updates on its pipeline, including the completion of AZURE-1 enrollment and AZURE-4 screening in March 2026. Multiple analysts raised price targets for Mirum Pharmaceuticals, leading to a consensus "Moderate Buy" rating. Company insiders have been net sellers recently.
Demand Seasonality affecting Mirum Pharmaceuticals, Inc.’s stock price
There is no explicit indication of significant demand seasonality for Mirum Pharmaceuticals' products and services. The company's focus on rare, debilitating liver diseases suggests a consistent medical need for its therapies rather than demand fluctuations tied to specific seasons.
Overview of Mirum Pharmaceuticals, Inc.’s business
Mirum Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare, debilitating liver diseases, particularly cholestatic liver conditions. Its commercial portfolio includes LIVMARLI (maralixibat), CHOLBAM (cholic acid), and CTEXLI (chenodiol). The company's pipeline includes Volixibat, Brelovitug, and MRM-3379.
MIRM’s Geographic footprint
Mirum Pharmaceuticals has a global footprint with approved products and has expanded its commercial reach to 33 countries. The company's products, particularly LIVMARLI, have seen strong sales contributions from both the U.S. and international markets.
MIRM Corporate Image Assessment
Mirum Pharmaceuticals has cultivated a positive brand reputation, driven by its strong financial performance, successful product development, and strategic acquisitions. Analyst ratings consistently lean towards "Moderate Buy" or "Buy," reflecting confidence in the company's trajectory and pipeline. The FDA approval of a new tablet formulation for LIVMARLI and the acquisition of Bluejay Therapeutics further enhance its reputation as an innovator in rare liver diseases.
Ownership
Mirum Pharmaceuticals, Inc. is a publicly traded company with its control heavily concentrated among institutional investors and funds. Major institutional owners include Frazier Life Sciences Management, L.P., Janus Henderson Group Plc, BlackRock, Inc., Vanguard Group Inc., State Street Corp, Eventide Asset Management, Llc and Price T Rowe Associates Inc /md/. The largest individual shareholder is Joshua Makower.
